142 related articles for article (PubMed ID: 29924569)
1. First comprehensive guideline released for the assessment of HER2 in patients with GEA.
Washington MK
MLO Med Lab Obs; 2017 Mar; 49(3):30-1. PubMed ID: 29924569
[No Abstract] [Full Text] [Related]
2. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
[TBL] [Abstract][Full Text] [Related]
3. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Arch Pathol Lab Med; 2016 Dec; 140(12):1345-1363. PubMed ID: 27841667
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
5. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
[No Abstract] [Full Text] [Related]
6. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
7. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
8. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
[TBL] [Abstract][Full Text] [Related]
9.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
10. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
11. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
12. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
13. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
14. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Bartley AN; Washington MK; Colasacco C; Ventura CB; Ismaila N; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
J Clin Oncol; 2017 Feb; 35(4):446-464. PubMed ID: 28129524
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
Hicks DG; Whitney-Miller C
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
[TBL] [Abstract][Full Text] [Related]
16. Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy.
Geldart T; Astras G
J Clin Oncol; 2011 Aug; 29(23):e664-5. PubMed ID: 21646609
[No Abstract] [Full Text] [Related]
17. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
18. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
20. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]